

Got the Urge to Merge?

Record pace of M&A deals transforms healthcare



of life sciences companies suffered a pandemic-fueled profit decline in 2020



expect a return to profitability in 2021 or 2022

Why CEOs say their **highest priorities** are accelerating portfolio reviews and M&As:

90%

of executives have conducted a comprehensive portfolio review

27%

are seeking M&As to acquire new products

22%

are looking to acquire talent



In Q1 2021 - M&A activity in the healthcare industry was up **more than 50%** over Q1 2020

Volume of announced and closed healthcare industry deals:


476

Q1 2020

723

Q1 2021

M&A Transactions - Q1 2021



Who will win the pricing battle?



Some pharmaceutical companies seek to **dominate** consumer healthcare, animal healthcare, oncology, etc.

If successful, they will have a significant competitive advantage and could **impact pricing** dramatically.



In response, health providers will secure **greater leverage** by creating larger GPOs.

Got the urge to learn more about **2021 Life Science trends?**

[READ THE BLOG](#)

Sources: Epstein Becker Green, KPMG, FocalPoint Partners, Bloomberg, EY

info@vistex.com | www.vistex.com

© Copyright 2021 Vistex, Inc. All rights reserved.

Vistex

Now it all adds up